# Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab

> **NCT00588900** · PHASE2 · TERMINATED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 5 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** cediranib maleate
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00588900
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2010-05
- **Final completion:** 2011-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588900, "Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00588900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*